ISM 5939
Alternative Names: ISM-5939Latest Information Update: 20 Dec 2024
Price :
$50 *
At a glance
- Originator InSilico Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 12 Dec 2024 InSilico Medicine Hong Kong Limited plans a phase Ia/b trial in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) (PO, Tablet), in December 2025(NCT06724042)
- 21 Nov 2024 Insilico Medicine receives IND clearance from US FDA for ISM 5939 for Solid tumours